Medications for inflammatory arthritis aim to control the immune response and reduce inflammation. These include steroids, which are generally not suitable for long-term use, and disease-modifying anti-rheumatic drugs (DMARDs). When introduced promptly under specialist care, these treatments can reduce symptoms and slow disease progression. Some people reach remission: inflammation is well controlled and symptoms are minimal or absent. A small proportion are even able to stop medication under specialist supervision.
Treatment for osteoarthritis focuses on managing pain and improving function. There are currently no medications that reverse the condition or target its underlying cause. Paracetamol, anti-inflammatory drugs such as ibuprofen, and steroid injections may help relieve symptoms. Non-drug approaches are important for both inflammatory arthritis and osteoarthritis. These include exercise, walking aids where needed, heat and cold therapies and some complementary approaches. Lifestyle also plays a key role. Maintaining a healthy weight, stopping smoking and staying physically active can all improve outcomes.
Why early assessment matters – and who to see first
Reaching specialist care quickly can make a significant difference. In the UK, new roles in primary care are helping people be assessed sooner. First contact physiotherapists (FCPs) working in GP surgeries can recognise early symptoms of inflammatory arthritis and refer patients to rheumatology specialists to begin appropriate treatment. They assess people with joint and muscle problems, request tests where appropriate and provide advice on treatment and long-term outlook. If specialist care is needed, they arrange referral directly.
First contact physiotherapists have been part of UK primary care for more than a decade. Evidence suggests the role is safe, cost effective and beneficial to patients, with patients reporting high satisfaction and doctors expressing confidence in physiotherapists’ expertise.
Arthritis is a leading cause of pain, stiffness and disability worldwide. For people with inflammatory forms of the disease, delayed recognition remains one of the biggest barriers to effective treatment. Symptoms can resemble more common joint problems, slowing referral to specialist care at the point when treatment would be most effective.